GreenGene™ F

Phase 3Biologic

GGreen Cross Corporation

GreenGene™ F is one of 34 biologic programs targeting Severe Hemophilia a. It is currently in Phase 3.

Indications

Total Trials

Active Trials

Competitors

Pipeline

Status by Indication[3][1]

Indication

Severe Hemophilia aActive, not recruiting

Severe Hemophilia aPhase 3

Active, not recruiting

Competition

Competitive Landscape

59 competitors in Severe Hemophilia a

#DrugCompanyPhaseTrials

Hemlibra

Roche

Phase 3

3 2

Efanesoctocog Alfa

Sanofi

Phase 3

2 3

Rfviiifc

BBioverativ Therapeutics Inc.

Approved

3 4

Advate

Takeda

Phase 3

4 5

Rituxan

Roche

Phase 2

1 6

Qfitlia

GGenzyme, a Sanofi Company

Phase 3

4 7

Bypassing Agents

Roche

Phase 3

1 8

Adynovate

Takeda

Approved

2 9

Recombinant Human Coagulation FVIII

Chia Tai Tianqing Pharmaceutical Group Co., Ltd.

Phase 3

1 10

Recombinant Factor VIII

Bayer

Phase 3

Ranked by pipeline maturity and clinical activity. Current drug highlighted in teal.

Clinical

Trials by Indication[1]

Severe Hemophilia a2 trials

Safety and Efficacy Extension Study of GreenGene™ F in Previously Treated Patients Diagnosed With Severe Hemophilia A

Unknown status·GGreen Cross Corporation·Phase 3·NCT02027779·150 enrolled

Safety, Efficacy and Pharmacokinetics of GreenGene™ F to Previously Treated Patients With Severe Hemophilia A

Unknown status·GGreen Cross Corporation·Phase 3·NCT01619046·124 enrolled

Sources

References

[1]
ClinicalTrials.gov — 2 trial records for GreenGene™ F. U.S. National Library of Medicine, National Institutes of Health.
[2]
ChEMBL — GreenGene™ F compound record. European Bioinformatics Institute (EMBL-EBI).
[3]
Open Targets Platform — Drug–disease associations for GreenGene™ F. EMBL-EBI & Wellcome Sanger Institute.
[4]
SEC EDGAR — Green Cross Corporation company filings. U.S. Securities and Exchange Commission.

Details

Drug Info

Quick Facts

Modality: Biologic[2]
Highest Phase: Phase 3[1]
Company: GGreen Cross Corporation

GreenGene™ F

Status by Indication[3][1]

Competitive Landscape

Trials by Indication[1]

Severe Hemophilia a2 trials

References

Drug Info

Quick Facts

Related News